Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms
- PMID: 33853885
- PMCID: PMC9488698
- DOI: 10.1183/16000617.0284-2020
Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms
Erratum in
-
"Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms." S. Malenfant, M. Lebret, É. Breton-Gagnon, et al. Eur Respir Rev 2021; 30: 200284.Eur Respir Rev. 2024 Feb 14;33(171):205284. doi: 10.1183/16000617.5284-2020. Print 2024 Jan 31. Eur Respir Rev. 2024. PMID: 38355152 Free PMC article.
Abstract
Exercise intolerance is a cardinal symptom of pulmonary arterial hypertension (PAH) and strongly impacts patients' quality of life (QoL). Although central cardiopulmonary impairments limit peak oxygen consumption (V' O2peak ) in patients with PAH, several peripheral abnormalities have been described over the recent decade as key determinants in exercise intolerance, including impaired skeletal muscle (SKM) morphology, convective O2 transport, capillarity and metabolism indicating that peripheral abnormalities play a greater role in limiting exercise capacity than previously thought. More recently, cerebrovascular alterations potentially contributing to exercise intolerance in patients with PAH were also documented. Currently, only cardiopulmonary rehabilitation has been shown to efficiently improve the peripheral components of exercise intolerance in patients with PAH. However, more extensive studies are needed to identify targeted interventions that would ultimately improve patients' exercise tolerance and QoL. The present review offers a broad and comprehensive analysis of the present literature about the complex mechanisms and their interactions limiting exercise in patients and suggests several gaps in knowledge that need to be addressed in the future for a better understanding of exercise intolerance in patients with PAH.
Copyright ©ERS 2021.
Conflict of interest statement
Conflict of interest: S. Malenfant has nothing to disclose. Conflict of interest: M. Lebret has nothing to disclose. Conflict of interest: É. Breton-Gagnon has nothing to disclose. Conflict of interest: F. Potus has nothing to disclose. Conflict of interest: R. Paulin has nothing to disclose. Conflict of interest: S. Bonnet has nothing to disclose. Conflict of interest: S. Provencher has nothing to disclose.
Figures




References
-
- Galie N, Humbert M, Vachiery JL, et al. . 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903–975. doi:10.1183/13993003.01032-2015 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical